Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| An early Transcriptomic Investigation in Adult Patients with Spinal Muscular Atrophy Under Treatment with Nusinersen. | J Mol Neurosci | 2024 | 39325116 | PubTator, text mining | PubMed |
| Molecular analysis of SMN2, NAIP, and GTF2H2 gene deletions and relationships with clinical subtypes of spinal muscular atrophy. | J Neurogenet | 2024 | 39321203 | PubTator, text mining | PubMed |
| Macrostructural Brain Abnormalities in Spinal Muscular Atrophy: A Case-Control Study. | Neurol Genet | 2024 | 39308455 | PubTator, text mining | PubMed |
| Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module. | Neuromuscul Disord | 2024 | 39299818 | PubTator, text mining | PubMed |
| Association among biomarkers, phenotypes, and motor milestones in Chinese patients with 5q spinal muscular atrophy types 1-3. | Front Neurol | 2024 | 39286802 | PubTator, text mining | PubMed |
| Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment. | Orphanet J Rare Dis | 2024 | 39272200 | PubTator, text mining | PubMed |
| Characterization of SMA type II skeletal muscle from treated patients shows OXPHOS deficiency and denervation. | JCI Insight | 2024 | 39264856 | PubTator, text mining | PubMed |
| Outcomes for patients in the RESTORE registry with spinal muscular atrophy and four or more SMN2 gene copies treated with onasemnogene abeparvovec. | Eur J Paediatr Neurol | 2024 | 39260228 | PubTator, text mining | PubMed |
| Thrombospondin-4 as potential cerebrospinal fluid biomarker for therapy response in pediatric spinal muscular atrophy. | J Neurol | 2024 | 39240344 | PubTator, text mining | PubMed |
| [Application of CNVPLUS-array custom microarray in genetic analysis of spinal muscular atrophy]. | Zhonghua Yi Xue Yi Chuan Xue Za Zhi | 2024 | 39217494 | PubTator, text mining | PubMed |
| Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study. | Eur J Pediatr | 2024 | 39210071 | PubTator, text mining | PubMed |
| Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges. | Genes (Basel) | 2024 | 39202360 | PubTator, text mining | PubMed |
| Ubiquitination Insight from Spinal Muscular Atrophy-From Pathogenesis to Therapy: A Muscle Perspective. | Int J Mol Sci | 2024 | 39201486 | PubTator, text mining | PubMed |
| Systematic Review of Presymptomatic Treatment for Spinal Muscular Atrophy. | Int J Neonatal Screen | 2024 | 39189228 | PubTator, text mining | PubMed |
| A CRISPR-dCas13 RNA-editing tool to study alternative splicing. | Nucleic Acids Res | 2024 | 39162234 | PubTator, text mining | PubMed |
| SMN1 c.5C>G (p.Ala2Gly) missense variant, a challenging molecular SMA diagnosis associated with mild disease, preserves SMN nuclear gems in patient-specific fibroblasts. | Front Genet | 2024 | 39139818 | PubTator, text mining | PubMed |
| Physiological Features of the Neural Stem Cells Obtained from an Animal Model of Spinal Muscular Atrophy and Their Response to Antioxidant Curcumin. | Int J Mol Sci | 2024 | 39125934 | PubTator, text mining | PubMed |
| Six-minute walk test as outcome measure of fatigability in adults with spinal muscular atrophy treated with nusinersen. | Muscle Nerve | 2024 | 39096012 | PubTator, text mining | PubMed |
| A rapid and easy-to-use spinal muscular atrophy screening tool based on primers with high specificity and amplification efficiency for SMN1 combined with single-stranded tag hybridization assay. | PLoS One | 2024 | 39088538 | PubTator, text mining | PubMed |
| U1 snRNA interactions with deep intronic sequences regulate splicing of multiple exons of spinal muscular atrophy genes. | Front Neurosci | 2024 | 39086841 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=14